Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Imaging of the autonomic nervous system in cardiac amyloidosis
Nuclear medicine imaging techniques
Published in: Nuclear Medicine and Radiologic Imaging in Sports Injuries
Access to document
10.1007/978-3-662-46491-5_3
Nuclear medicine is a rapidly developing field which focuses on the imaging of physiological processes and the evaluation of treatment of specific diseases. It involves the use of radiopharmaceuticals for both purposes. Different radiopharmaceuticals have different kinetics and can therefore be used to image processes in the body, the function of an organ or the presence of a specific cellular target. In sports medicine, bone scintigraphy and leukocyte scintigraphy play important roles. Radiopharmaceuticals in bone scintigraphy are diphosphonate complexes which are absorbed onto the hydroxyapatite crystal of newly...
Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer
Published in: Cancer Discovery
Access to document
10.1158/2159-8290.CD-14-0697
It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer. We performed a feasibility study to assess ER availability before and during fulvestrant. Sixteen patients with ER-positive metastatic breast cancer underwent positron emission tomography/computed tomography (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18 F] fluoroestradiol (FES) uptake. Incomplete reduction in ER availability was predefined as = 1.5. In total, 131 FES-positive lesions...
Michel van Kruchten, Elisabeth G. de Vries, Andor W. Glaudemans, Meta C. van Lanschot, Martijn van Faassen, Ido P. Kema, Myles Brown, Carolien P. Schröder, Erik F. de Vries, Geke A. Hospers
Large-Vessel Vasculitis: Interobserver Agreement and Diagnostic Accuracy of (18)F-FDG-PET/CT
Published in: Biomed Research International
Access to document
10.1155/2015/914692
document
Introduction. F-18-FDG-PET visualises inflammation. Both atherosclerosis and giant cell arteritis cause vascular inflammation, but distinguishing the two may be difficult. The goal of this study was to assess interobserver agreement and diagnostic accuracy of F-18-FDG-PET for the detection of large artery involvement in giant cell arteritis (GCA). Methods. 31 F-18-FDG-PET/CT scans were selected from 2 databases. Four observers assessed vascularwall F-18-FDGuptake, initially without and subsequently with predefined observer criteria (i.e., vascular wall F-18-FDG uptake compared to liver or femoral artery F-18-FDG uptake). External validation was performed by two...
K. D. F. Lensen, E. F. I. Comans, A. E. Voskuyl, C. J. van der Laken, E. Brouwer, A. T. Zwijnenburg, L. M. Pereira Arias-Bouda, A. W. J. M. Glaudemans, R. H. J. A. Slart, Y. M. Smulders
Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using 16 alpha-F-18-Fluoro-17 beta-Estradiol PET/CT
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.114.147579
The estrogen receptor a (ER alpha) is expressed in approximately 70% of ovarian cancer tumors. PET of tumor ER alpha expression with the tracer 16 alpha-F-18-fluoro-17 beta-estradiol (F-18-FES) may be valuable to select ovarian cancer patients for endocrine therapy. The aim of this study was to evaluate the feasibility of F-18-FES PET to determine tumor ERa expression noninvasively in epithelial ovarian cancer patients. Methods: F-18-FES PET/CT was performed shortly before cytoreductive surgery. Tumor F-18-FES uptake was quantified for all lesions 10 mm or greater on CT and expressed...
Michel van Kruchten, Erik F. J. de Vries, Henriette J. G. Arts, Neeltina M. Jager, Alphons H. H. Bongaerts, Andor W. J. M. Glaudemans, Harry Hollema, Elisabeth G. E. de Vries, Geke A. P. Hospers, Anna K. L. Reyners